KIMBERLY MCARTHUR: Open Payments
NPI 1659811388 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 29 payments from 10 companies in 2025. Trend: 2023 $292 · 2024 $1,005 · 2025 $899
Food & beverage: $800Education: $99
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 7 | $265 |
| Regeneron Healthcare Solutions, Inc. | 6 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $132 |
| SANOFI-AVENTIS U.S. LLC | 1 | $99 |
| Novartis Pharmaceuticals Corporation | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 2 | $45 |
| Galderma Laboratories, L.P. | 1 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Organon LLC | 2 | $30 |
| Grifols USA, LLC | 1 | $29 |
Products named: DUPIXENT, CUVITRU, Rhapsido, NEMLUVIO, TALTZ, Prolastin-C Liquid, FASENRA, AIRSUPRA.
Industry payments across MD — which companies pay providers there.
